
  
    
      
        Background_NNP
        The_DT breast_NN and_CC ovarian_NN cancer_NN susceptibility_NN gene_NN ,_,
        BRCA_NNP 1_CD ,_, is_VBZ located_VBN at_IN 17_CD q_NN 21_CD ,_, and_CC encodes_NNS a_DT 1863_CD amino_JJ acid_NN
        protein_NN ._. Mutations_NNP in_IN this_DT gene_NN account_NN for_IN 60_CD %_NN of_IN
        hereditary_JJ ovarian_NN cancers_NNS [_NN 1_CD ]_NN ._. Loss_NN of_IN heterozygosity_NN
        in_IN this_DT gene_NN occurs_VBZ in_IN 30_CD -_: 70_CD %_NN of_IN sporadic_JJ ovarian_NN
        carcinomas_NNS [_NN 2_CD ]_NN ._. Species_NNP homology_NN studies_NNS have_VBP shown_VBN that_IN
        while_IN the_DT entire_JJ 22_CD exon_NN gene_NN is_VBZ poorly_RB conserved_JJ ,_, the_DT
        terminal_NN ends_VBZ maintain_VB over_IN an_DT 80_CD %_NN homology_NN between_IN rat_NN ,_,
        human_NN and_CC mouse_NN [_NN 3_CD ]_NN ._. BRCA_NNP 1_CD has_VBZ long_RB been_VBN known_VBN to_TO
        function_VB in_IN DNA_NNP repair_NN ._. Studies_NNS have_VBP shown_VBN BRCA_NNP 1_CD is_VBZ
        upregulated_JJ in_IN cells_NNS treated_VBN by_IN DNA_NNP damaging_JJ agents_NNS such_JJ as_IN
        cisplatinum_NN [_NN 4_CD ]_NN ._. BRCA_NNP 1_CD has_VBZ been_VBN shown_VBN to_TO interact_NN with_IN
        DNA_NNP repair_NN proteins_NNS such_JJ as_IN Rad_NNP 50_CD and_CC Rad_NNP 51_CD ,_, the_DT tumor_NN
        suppressor_NN genes_NNS RB_NNP and_CC BRCA_NNP 2_CD ,_, transcriptional_NN factors_NNS (_( RNA_NNP
        pol_NN II_NNP ,_, histone_NN deacetylase_NN complex_JJ ,_, ctIP_NN )_) as_RB well_RB as_IN
        influence_NN numerous_JJ cyclins_NNS and_CC cyclin_NN dependent_JJ kinases_NNS
        contributing_VBG to_TO cell_NN cycle_NN regulation_NN [_NN 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD 12_CD
        ]_NN ._. More_RBR recently_RB ,_, BRCA_NNP 1_CD has_VBZ been_VBN shown_VBN to_TO influence_VB
        apoptosis_NNS in_IN a_DT p_NN 53_CD independent_JJ manner_NN [_NN 13_CD ]_NN ._. This_DT
        apoptotic_JJ response_NN involved_VBD the_DT c-jun_JJ kinase_NN (_( JNK_NNP )_) pathway_NN ,_,
        though_IN the_DT details_NNS of_IN this_DT mechanism_NN remain_VB unclear_JJ [_NN 14_CD ]_NN
        ._.
        The_DT highly_RB acidic_JJ carboxy-terminal_JJ (_( BRCT_NNP )_) region_NN of_IN
        BRCA_NNP 1_CD has_VBZ been_VBN suggested_VBN to_TO play_VB a_DT role_NN in_IN transactivation_NN
        [_NN 11_CD ]_NN ._. BRCT_NNP interacts_NNS with_IN BRCA_NNP 2_CD ,_, Rad_NNP 51_CD ,_, other_JJ tumor_NN
        suppressing_VBG elements_NNS ,_, as_RB well_RB as_IN numerous_JJ transcription_NN
        factors_NNS ,_, such_JJ as_IN RNA_NNP helicase_NN A_DT and_CC STAT_NNP 1_CD [_NN 15_CD 16_CD ]_NN ._.
        Recently_RB ,_, it_PRP has_VBZ been_VBN discovered_VBN that_DT truncation_NN of_IN this_DT
        region_NN resulted_VBD in_IN suppression_NN of_IN apoptosis_NNS following_VBG
        pro-apoptotic_JJ stimuli_NNS [_NN 17_CD ]_NN ._. Further_RB ,_, these_DT studies_NNS also_RB
        suggested_VBD that_IN the_DT BRCT_NNP region_NN facilitates_NNS apoptotic_JJ
        functions_NNS within_IN the_DT caspase_NN pathway_NN ._.
        The_DT amino_JJ terminal_NN (_( BRNT_NNP )_) of_IN BRCA_NNP 1_CD contains_VBZ a_DT highly_RB
        conserved_JJ zinc_NN binding_JJ or_CC RING_NNP finger_NN domain_NN also_RB involved_VBD
        in_IN multiple_JJ functions_NNS within_IN the_DT cell_NN ._. Molecular_NNP modeling_NN
        has_VBZ shown_VBN that_IN this_DT domain_NN contains_VBZ two_CD zinc_NN finger-like_JJ
        motifs_NNS connected_VBN through_IN linking_VBG C_NNP 
        3_CD HC_NNP 
        4_CD regions_NNS [_NN 18_CD ]_NN ._. Naturally_RB occurring_VBG
        splice_NN variants_NNS of_IN the_DT gene_NN suggest_VBP at_IN least_JJS two_CD
        transcription_NN initiation_NN points_NNS above_IN and_CC below_IN the_DT coding_VBG
        region_NN for_IN the_DT RING_NNP domain_NN [_NN 19_CD ]_NN ._. Truncation_NNP studies_NNS have_VBP
        shown_VBN that_IN the_DT RING_NNP domain_NN may_MD function_VB in_IN direct_JJ protein_NN
        binding_JJ of_IN ER-α_NNP ,_, ATF_NNP 1_CD ,_, and_CC BARD_NNP 1_CD ,_, a_DT ubiquitin_NN ligase_NN [_NN 20_CD
        21_CD 22_CD ]_NN ._. While_IN zinc_NN RING_NNP domains_NNS are_VBP common_JJ motifs_NNS in_IN
        several_JJ protein_NN families_NNS such_JJ as_IN oncoproteins_NNS and_CC
        regulatory_JJ proteins_NNS ,_, the_DT actual_JJ function_NN of_IN the_DT domain_NN
        differs_VBZ among_IN these_DT proteins_NNS ._. For_IN example_NN ,_, inhibitors_NNS of_IN
        apoptosis_NNS proteins_NNS ,_, (_( IAPs_NNP )_) ,_, contain_VB one_CD to_TO three_CD tandem_JJ
        baculovirus_JJ inverted_JJ repeat_NN (_( BIR_NNP )_) domains_NNS as_RB well_RB as_IN a_DT
        carboxy_NN terminal_NN RING_NNP domain_NN ._. Previous_JJ studies_NNS have_VBP shown_VBN
        this_DT RING_NNP domain_NN essential_JJ in_IN the_DT anti-apoptotic_JJ function_NN
        of_IN some_DT IAPs_NNP [_NN 23_CD ]_NN ._.
        The_DT most_RBS common_JJ mode_NN a_DT cell_NN uses_VBZ to_TO undergo_VB apoptosis_NNS is_VBZ
        the_DT cysteine-aspartate_JJ specific_JJ protease_NN (_( caspase_NN )_) pathway_NN ._.
        This_DT proteolytic_JJ cascade_NN may_MD be_VB triggered_VBN by_IN a_DT wide_JJ variety_NN
        of_IN stimuli_NNS and_CC employs_VBZ numerous_JJ initiation_NN routes_NNS within_IN
        the_DT cell_NN ._. While_IN there_EX is_VBZ extensive_JJ crosstalk_NN between_IN the_DT
        caspases_NNS ,_, the_DT two_CD most_RBS common_JJ initiator_NN pathways_NNS are_VBP the_DT
        Fas_NNP /_NN Fas_NNP ligand_NN pathway_NN ,_, involving_VBG caspase_NN 8_CD and_CC caspase_NN 10_CD ,_,
        and_CC the_DT mitochondrial_NN pathway_NN ,_, triggering_VBG caspase_NN 9_CD [_NN 24_CD 25_CD
        ]_NN ._. Caspase_NNP 3_CD ,_, a_DT pivotal_JJ downstream_JJ protease_NN ,_, functions_NNS in_IN
        virtually_RB every_DT caspase_NN pathway_NN and_CC serves_VBZ as_IN an_DT
        executioner_NN in_IN the_DT cells_NNS by_IN cleavage_NN of_IN downstream_JJ targets_NNS
        which_WDT lead_VBP to_TO irreversible_JJ chromosomal_NN degradation_NN ._. Perhaps_RB
        the_DT most_RBS prominent_JJ caspase_NN 3_CD substrate_NN is_VBZ DNA_NNP Fragmentation_NNP
        Factor_NN 45_CD (_( DFF_NNP 45_CD )_) ,_, an_DT inhibitor_NN of_IN caspase-activated_JJ DNase_NNP
        [_NN 26_CD ]_NN ._. Following_VBG caspase_NN 3_CD -_: mediated_JJ cleavage_NN ,_, DFF_NNP 45_CD
        releases_NNS DFF_NNP 40_CD ,_, the_DT DNase_NNP responsible_JJ for_IN DNA_NNP fragmentation_NN
        into_IN the_DT characteristic_JJ apoptotic_JJ DNA_NNP ladder_NN ._. Caspase_NNP 3_CD
        also_RB deactivates_VBZ vital_JJ DNA_NNP repair_NN enzymes_NNS such_JJ as_IN poly_RB
        ribose_NN ADP_NNP polymerase_NN (_( PARP_NNP )_) [_NN 27_CD ]_NN ._. Cleavage_NNP of_IN PARP_NNP has_VBZ
        been_VBN regarded_VBN as_IN a_DT hallmark_NN of_IN caspase-dependent_JJ apoptosis_NNS
        [_NN 28_CD ]_NN ._.
        No_DT study_NN to_TO date_NN has_VBZ explored_JJ the_DT possible_JJ involvement_NN
        of_IN the_DT BRCA_NNP 1_CD amino-terminal_JJ RING_NNP domain_NN in_IN caspase-mediated_JJ
        apoptosis_NNS ._. Therefore_RB ,_, ovarian_NN surface_NN epithelial_NN cell_NN lines_NNS
        with_IN and_CC without_IN the_DT 185_CD delAG_NN BRCA_NNP 1_CD mutation_NN were_VBD used_VBN to_TO
        ascertain_VB whether_IN the_DT RING_NNP domain_NN of_IN the_DT amino-terminal_JJ
        affected_VBN apoptosis_NNS ._. This_DT mutation_NN ,_, common_JJ among_IN families_NNS
        with_IN hereditary_JJ ovarian_NN cancer_NN ,_, is_VBZ a_DT frameshift_NN mutation_NN
        occurring_VBG at_IN the_DT beginning_NN of_IN the_DT C_NNP 
        3_CD HC_NNP 
        4_CD region_NN of_IN exon_NN 2_CD that_IN essentially_RB
        interrupts_NNS RING_NNP domain_NN function_NN [_NN 19_CD 29_CD 30_CD ]_NN ._. The_DT results_NNS
        showed_VBD that_DT disruption_NN of_IN the_DT BRCA_NNP 1_CD amino-terminal_JJ RING_NNP
        domain_NN altered_VBD caspase_NN 3_CD activation_NN and_CC subsequent_JJ DFF_NNP 45_CD
        and_CC PARP_NNP cleavage_NN ,_, resulting_VBG in_IN accelerated_VBD STS-induced_NNP
        apoptosis_NNS ._.
      
      
        Results_NNS
        
          Loss_NN of_IN BRCA_NNP 1_CD expression_NN resulted_VBD in_IN increased_VBN cell_NN
          death_NN when_WRB exposed_VBN to_TO 1_CD μM_NN staurosporine_NN treatment_NN
          SV-_NNP 40_CD large_JJ T_NN antigen_NN transfected_JJ ovarian_NN surface_NN
          epithelial_NN cell_NN lines_NNS from_IN women_NNS with_IN and_CC without_IN an_DT
          amino-terminal_JJ BRCA_NNP 1_CD mutation_NN were_VBD employed_VBN to_TO ascertain_VB
          the_DT function_NN of_IN the_DT amino-terminal_JJ RING_NNP domain_NN in_IN
          apoptosis_NNS [_NN 31_CD ]_NN ._. To_TO confirm_VB BRCA_NNP 1_CD status_NN in_IN these_DT cell_NN
          lines_NNS ,_, whole_JJ cell_NN lysates_NNS were_VBD western_JJ blotted_JJ using_VBG a_DT
          monoclonal_NN anti-_NN BRCA_NNP 1_CD antibody_NN against_IN the_DT amino-terminal_JJ
          (_( Figure_NN 1_LS )_) ._. Using_VBG the_DT MCF_NNP 7_CD breast_NN carcinoma_NN cell_NN line_NN as_IN
          a_DT positive_JJ control_NN ,_, MCC_NNP 5_CD cells_NNS expressed_VBD the_DT full_JJ length_NN
          216_CD kDa_NN BRCA_NNP 1_CD protein_NN and_CC were_VBD confirmed_VBN BRCA_NNP 1_CD wt_NN ._. In_IN
          contrast_NN ,_, the_DT HIO_NNP 3261_CD -_: 77_CD cells_NNS were_VBD found_VBN to_TO have_VB
          significantly_RB reduced_VBN levels_NNS of_IN full_JJ length_NN BRCA_NNP 1_CD than_IN
          the_DT wild_JJ type_NN cell_NN line_NN ,_, confirming_VBG the_DT mutated_VBN
          amino-terminal_JJ BRCA_NNP 1_CD (_( BRCA_NNP 1_CD +_NN )_) in_IN these_DT cells_NNS ._. Due_JJ to_TO the_DT
          high_JJ molecular_JJ weight_NN of_IN BRCA_NNP 1_CD ,_, actin_NN could_MD not_RB be_VB used_VBN
          as_IN a_DT loading_NN control_NN ._. Thus_RB ,_, the_DT membranes_NNS were_VBD stained_JJ
          with_IN 7_CD %_NN Amido_NNP black_JJ with_IN the_DT protein_NN front_NN used_VBN as_IN a_DT
          loading_NN control_NN ._.
          Having_VBG confirmed_VBN the_DT BRCA_NNP 1_CD status_NN of_IN these_DT cell_NN lines_NNS ,_,
          cell_NN viability_NN was_VBD then_RB assayed_JJ under_IN cytotoxic_JJ stress_NN ._.
          Cells_NNP were_VBD treated_VBN with_IN 1_CD μM_NN STS_NNP for_IN 3_CD h_NN and_CC subjected_VBN to_TO
          MTS_NNP assay_NN at_IN 0_CD ,_, 24_CD ,_, and_CC 48_CD h_NN (_( Figure_NN 2_CD A_DT )_) ._. Results_NNS were_VBD
          reported_VBN as_IN percent_NN growth_NN of_IN respective_JJ untreated_JJ cells_NNS
          allowed_VBN to_TO grow_VB in_IN serum_NN containing_VBG media_NNS ._. BRCA_NNP 1_CD wt_NN cells_NNS
          grew_VBD 17_CD %_NN greater_JJR at_IN 24_CD h_NN and_CC 8_CD %_NN greater_JJR at_IN 48_CD h_NN than_IN
          BRCA_NNP 1_CD +_NN cells_NNS ._. This_DT difference_NN proved_VBD to_TO be_VB statistically_RB
          significant_JJ (_( p_NN <_NN ._. 03_CD and_CC p_NN <_NN ._. 01_CD ,_, respectively_RB )_) ._.
          BRCA_NNP 1_CD wt_NN cells_NNS appeared_VBD to_TO recover_VB at_IN 72_CD h_NN while_IN BRCA_NNP 1_CD +_NN
          cells_NNS continued_VBD to_TO decline_VB in_IN growth_NN (_( data_NNS not_RB
          shown_VBN )_) ._.
          To_TO confirm_VB that_IN the_DT difference_NN in_IN cell_NN viability_NN was_VBD
          due_JJ to_TO alterations_NNS in_IN survival_NN response_NN after_IN STS_NNP
          treatment_NN and_CC not_RB an_DT intrinsic_JJ property_NN of_IN the_DT individual_JJ
          cell_NN lines_NNS ,_, growth_NN of_IN both_DT cell_NN lines_NNS was_VBD examined_VBN by_IN MTS_NNP
          assay_NN under_IN the_DT same_JJ conditions_NNS in_IN the_DT absence_NN of_IN STS_NNP
          (_( Figure_NN 2_CD B_NNP )_) ._. Linear_NNP regression_NN analysis_NN of_IN cell_NN growth_NN
          revealed_VBD that_IN the_DT slopes_NNS of_IN the_DT BRCA_NNP 1_CD wt_NN cells_NNS ,_, (_( 0_CD ._. 12_CD )_) and_CC
          that_IN of_IN the_DT BRCA_NNP 1_CD +_NN cells_NNS ,_, (_( 0_CD ._. 14_CD )_) were_VBD essentially_RB the_DT
          same_JJ ._.
          To_TO ensure_VB the_DT survival_NN difference_NN after_IN STS_NNP treatment_NN
          seen_VBN between_IN the_DT BRCA_NNP 1_CD wt_NN and_CC BRCA_NNP 1_CD +_NN cells_NNS was_VBD associated_VBN
          with_IN cell_NN death_NN ,_, a_DT trypan_NN blue_JJ exclusion_NN assay_NN was_VBD
          conducted_VBN (_( Figure_NN 2_CD C_NNP )_) ._. Cells_NNP were_VBD plated_JJ in_IN triplicate_NN
          and_CC both_DT adherent_NN and_CC suspended_VBN cell_NN populations_NNS were_VBD
          assayed_JJ with_IN results_NNS reported_VBD as_IN percent_NN of_IN total_JJ
          population_NN dead_JJ ._. No_DT appreciable_JJ difference_NN was_VBD observed_VBN
          in_IN the_DT amount_NN of_IN death_NN between_IN the_DT cell_NN lines_NNS at_IN 0_CD ,_, 1_CD ,_, or_CC
          3_CD h_NN (_( 1_CD %_NN ,_, 3_CD ._. 5_CD %_NN ,_, and_CC 2_CD ._. 5_CD %_NN ,_, respectively_RB )_) ._. There_EX was_VBD ,_,
          however_RB ,_, a_DT significantly_RB higher_JJR percentage_NN of_IN dead_JJ cells_NNS
          in_IN the_DT BRCA_NNP 1_CD +_NN cell_NN line_NN at_IN 24_CD h_NN (_( 12_CD ._. 8_CD %_NN ;_: p_NN <_NN ._. 027_CD )_) and_CC
          48_CD h_NN (_( 24_CD ._. 6_CD %_NN ;_: p_NN <_NN ._. 001_CD )_) ._.
        
        
          Amino-terminal_NNP BRCA_NNP 1_CD mutation_NN was_VBD associated_VBN with_IN
          elevated_JJ caspase_NN 3_CD activation_NN following_VBG STS_NNP
          treatment_NN
          To_TO investigate_VB the_DT role_NN of_IN amino-terminal_JJ of_IN BRCA_NNP 1_CD in_IN
          apoptosis_NNS ,_, the_DT effect_NN of_IN STS_NNP was_VBD examined_VBN on_IN elements_NNS of_IN
          the_DT caspase_NN pathway_NN (_( Figure_NN 3_LS )_) ._. First_LS ,_, to_TO determine_VB
          whether_IN a_DT mutation_NN in_IN amino-terminal_JJ RING_NNP domain_NN of_IN BRCA_NNP 1_CD
          preferentially_RB targeted_VBN either_CC the_DT mitochondrial_NN [_NN 25_CD ]_NN
          or_CC Fas_NNP /_NN Fas_NNP ligand_NN apoptotic_JJ pathway_NN [_NN 24_CD ]_NN ,_, levels_NNS of_IN
          the_DT respective_JJ initiator_NN caspases_NNS 9_CD and_CC 8_CD were_VBD
          determined_VBN ._. Both_DT cell_NN lines_NNS produced_VBN activated_VBN caspases_NNS 8_CD
          and_CC 9_CD by_IN 1_CD h_NN after_IN treatment_NN with_IN equivalent_NN levels_NNS at_IN 3_CD
          h_NN ._.
          Next_JJ ,_, levels_NNS of_IN the_DT executioner_NN caspase_NN 3_CD were_VBD
          examined_VBN ._. Once_RB more_JJR ,_, both_DT cell_NN lines_NNS produced_VBN activated_VBN
          caspase_NN 3_CD by_IN 1_CD h_NN after_IN treatment_NN ._. However_RB ,_, BRCA_NNP 1_CD +_NN cells_NNS
          showed_VBD significantly_RB more_RBR active_JJ caspase_NN 3_CD by_IN 3_CD h_NN after_IN
          treatment_NN than_IN the_DT wild_JJ type_NN ._. To_TO quantify_VB the_DT difference_NN
          in_IN caspase_NN activation_NN ,_, the_DT immunoblots_NNS were_VBD scanned_JJ and_CC
          analyzed_VBD via_IN ImagQuant_NNP densitometry_NN (_( Table_NNP 1_LS )_) ._.
          Densitometric_NNP analysis_NN revealed_VBD that_IN although_IN BRCA_NNP 1_CD +_NN
          cells_NNS initially_RB had_VBD lower_JJR levels_NNS of_IN caspase_NN 3_CD ,_, after_IN 3_CD h_NN
          STS_NNP treatment_NN ,_, caspase_NN 3_CD levels_NNS were_VBD 72_CD %_NN higher_RBR ._. Levels_NNP
          of_IN STS-induced_NNP caspase_NN 7_CD ,_, a_DT structural_JJ and_CC functional_JJ
          homolog_NN of_IN caspase_NN 3_CD [_NN 32_CD ]_NN were_VBD also_RB evaluated_VBN (_( Figure_NN
          3_LS )_) ._. Procaspase_NNP 7_CD began_VBD to_TO be_VB cleaved_JJ at_IN 1_CD h_NN of_IN treatment_NN
          and_CC was_VBD completely_RB processed_VBN by_IN 3_CD h_NN of_IN treatment_NN in_IN both_DT
          BRCA_NNP 1_CD wt_NN and_CC BRCA_NNP 1_CD +_NN cells_NNS ._. Although_IN caspase_NN 7_CD plays_VBZ a_DT
          subsidiary_NN role_NN in_IN DNA_NNP fragmentation_NN and_CC apoptosis_NNS
          morphology_NN [_NN 33_CD ]_NN ,_, densitometric_JJ analysis_NN illustrated_VBN
          that_IN BRCA_NNP 1_CD +_NN cells_NNS contained_VBD substantially_RB reduced_VBN levels_NNS
          of_IN procaspase_NN 7_CD in_IN untreated_JJ cells_NNS (_( 39_CD %_NN of_IN that_DT seen_VBN in_IN
          BRCA_NNP 1_CD wt_NN )_) ,_, and_CC during_IN initial_JJ STS_NNP treatment_NN (_( 31_CD %_NN of_IN that_DT
          seen_VBN in_IN BRCA_NNP 1_CD wt_NN at_IN 0_CD ._. 5_CD h_NN )_) ._.
          To_TO determine_VB whether_IN elevated_VBD levels_NNS of_IN cleaved_JJ
          caspase_NN 3_CD resulted_VBD in_IN increased_VBN cleavage_NN of_IN caspase_NN 3_CD
          substrates_NNS ,_, DFF_NNP 45_CD cleavage_NN was_VBD studied_VBN (_( Figure_NN 3_LS )_) ._.
          Degradation_NNP of_IN full_JJ length_NN DFF_NNP 45_CD was_VBD used_VBN to_TO indicate_VB
          caspase_NN 3_CD activity_NN ._. In_IN both_DT cell_NN lines_NNS ,_, DFF_NNP 45_CD began_VBD to_TO
          significantly_RB degrade_NN by_IN 1_CD h_NN after_IN treatment_NN ._. In_IN BRCA_NNP 1_CD wt_NN
          cells_NNS ,_, the_DT levels_NNS of_IN full_JJ length_NN DFF_NNP 45_CD were_VBD 95_CD %_NN of_IN
          control_NN at_IN 0_CD ._. 5_CD h_NN ,_, 40_CD %_NN of_IN control_NN at_IN 1_CD h_NN ,_, and_CC 22_CD %_NN of_IN
          control_NN at_IN 1_CD ._. 5_CD h_NN ._. In_IN contrast_NN ,_, in_IN BRCA_NNP 1_CD +_NN cells_NNS ,_, full_JJ
          length_NN DFF_NNP 45_CD was_VBD only_RB 71_CD %_NN of_IN control_NN at_IN 0_CD ._. 5_CD h_NN ,_, 16_CD %_NN of_IN
          control_NN at_IN 1_CD h_NN ,_, and_CC 10_CD %_NN of_IN control_NN at_IN 1_CD ._. 5_CD h_NN (_( Table_NNP
          1_LS )_) ._.
        
        
          Amino-terminal_NNP BRCA_NNP 1_CD mutation_NN caused_VBN increased_VBN
          degradation_NN of_IN caspase-linked_JJ DNA_NNP repair_NN proteins_NNS
          To_TO ascertain_VB whether_IN increased_VBN caspase_NN 3_CD activity_NN in_IN
          BRCA_NNP 1_CD +_NN cells_NNS could_MD also_RB affect_VB DNA_NNP repair_NN pathways_NNS ,_, the_DT
          DNA_NNP repair_NN enzymes_NNS PARP_NNP ,_, a_DT known_VBN substrate_NN of_IN caspase_NN 3_CD ,_,
          [_NN 27_CD ]_NN and_CC ERCC_NNP 1_CD ,_, a_DT repair_NN protein_NN not_RB dependent_JJ on_IN
          caspase_NN 3_CD [_NN 35_CD ]_NN were_VBD examined_VBN (_( Figure_NN 4_LS )_) ._. Interestingly_RB ,_,
          cleavage_NN and_CC inactivation_NN of_IN PARP_NNP was_VBD noted_VBN only_RB at_IN 3_CD h_NN
          after_IN STS_NNP treatment_NN in_IN BRCA_NNP 1_CD wt_NN cells_NNS ._. In_IN contrast_NN ,_,
          accelerated_VBD cleavage_NN and_CC inactivation_NN of_IN PARP_NNP was_VBD seen_VBN in_IN
          BRCA_NNP 1_CD +_NN cells_NNS as_RB early_RB as_IN 1_CD h_NN after_IN STS_NNP treatment_NN ._. Levels_NNP
          of_IN ERCC_NNP 1_CD were_VBD not_RB significantly_RB different_JJ between_IN BRCA_NNP 1_CD wt_NN
          and_CC BRCA_NNP 1_CD +_NN cells_NNS ._.
        
      
      
        Discussion_NNP
        A_DT frameshift_NN mutation_NN in_IN the_DT amino-terminal_JJ of_IN the_DT BRCA_NNP 1_CD
        gene_NN disrupts_NNS the_DT RING_NNP domain_NN and_CC all_DT domains_NNS after_IN it_PRP ._. Our_PRP$
        data_NNS showed_VBD that_IN a_DT BRCA_NNP 1_CD mutation_NN interrupting_VBG the_DT RING_NNP
        domain_NN altered_VBD apoptosis_NNS in_IN ovarian_NN surface_NN epithelial_NN
        cells_NNS ._. While_IN there_EX was_VBD no_DT difference_NN in_IN overall_JJ growth_NN
        between_IN BRCA_NNP 1_CD +_NN and_CC BRCA_NNP 1_CD wt_NN cells_NNS ,_, BRCA_NNP 1_CD +_NN cells_NNS showed_VBD a_DT
        marked_VBN reduction_NN in_IN survival_NN following_VBG STS_NNP treatment_NN ._.
        Reduced_NNP cellular_JJ survival_NN in_IN BRCA_NNP 1_CD +_NN cells_NNS was_VBD associated_VBN
        with_IN increased_VBN cell_NN death_NN due_JJ to_TO alterations_NNS in_IN apoptosis_NNS ._.
        No_DT difference_NN was_VBD detected_VBN in_IN the_DT levels_NNS of_IN caspase_NN 9_CD or_CC
        caspase_NN 8_CD among_IN the_DT BRCA_NNP 1_CD +_NN or_CC BRCA_NNP 1_CD wt_NN cells_NNS ,_, suggesting_VBG
        that_IN the_DT reduced_VBN cell_NN survival_NN in_IN BRCA_NNP 1_CD +_NN cells_NNS was_VBD not_RB
        associated_VBN with_IN a_DT difference_NN in_IN initiation_NN of_IN either_DT the_DT
        mitochondrial_NN or_CC the_DT Fas_NNP /_NN FasL_NNP apoptotic_JJ pathways_NNS ._. In_IN
        contrast_NN ,_, STS_NNP induced_VBD 72_CD %_NN greater_JJR caspase_NN 3_CD activity_NN in_IN
        BRCA_NNP 1_CD +_NN compared_VBN to_TO BRCA_NNP 1_CD wt_NN cells_NNS ._. The_DT enhanced_JJ caspase_NN 3_CD
        activity_NN in_IN BRCA_NNP 1_CD +_NN cells_NNS was_VBD clearly_RB functional_JJ and_CC
        resulted_VBD in_IN increased_VBN proteolysis_NNS of_IN downstream_JJ targets_NNS of_IN
        caspase_NN 3_CD ._. That_DT is_VBZ ,_, we_PRP found_VBD 40_CD %_NN less_RBR full_JJ length_NN DFF_NNP 45_CD at_IN
        1_CD h_NN and_CC 42_CD %_NN less_JJR at_IN 1_CD ._. 5_CD h_NN in_IN BRCA_NNP 1_CD +_NN cells_NNS compared_VBN with_IN
        BRCA_NNP 1_CD wt_NN cells_NNS ._. The_DT cleavage_NN and_CC subsequent_JJ deactivation_NN of_IN
        this_DT caspase_NN 3_CD -_: dependent_JJ DNase_NNP inhibitor_NN suggested_VBD that_IN
        amino-terminal_JJ BRCA_NNP 1_CD mutations_NNS enhance_VB cellular_JJ apoptosis_NNS
        contributing_VBG to_TO poor_JJ cell_NN survival_NN ._.
        With_IN BRCA_NNP 1_CD 's_POS extensive_JJ connection_NN to_TO DNA_NNP repair_NN already_RB
        established_VBD [_NN 35_CD ]_NN ,_, we_PRP also_RB examined_VBD whether_IN an_DT
        amino-terminal_JJ BRCA_NNP 1_CD mutation_NN reduced_VBD cellular_JJ survival_NN by_IN
        enhanced_JJ caspase_NN 3_CD -_: dependent_JJ cleavage_NN and_CC subsequent_JJ
        inactivation_NN of_IN the_DT caspase_NN 3_CD -_: dependent_JJ DNA_NNP repair_NN enzyme_NN
        PARP_NNP ._. As_IN with_IN DFF_NNP 45_CD ,_, PARP_NNP cleavage_NN was_VBD significantly_RB
        enhanced_VBN in_IN BRCA_NNP 1_CD +_NN cells_NNS suggesting_VBG that_WDT decreased_VBD DNA_NNP
        repair_NN capacity_NN in_IN BRCA_NNP 1_CD +_NN cells_NNS may_MD ,_, in_IN part_NN ,_, be_VB due_JJ to_TO
        premature_JJ inactivation_NN of_IN PARP_NNP ._. This_DT pattern_NN was_VBD not_RB seen_VBN
        with_IN ERCC_NNP 1_CD and_CC may_MD be_VB due_JJ to_TO the_DT choice_NN of_IN apoptotic_JJ
        stimulus_NN used_VBN ._. While_IN the_DT exact_JJ mechanism_NN remains_VBZ unclear_JJ ,_,
        STS_NNP has_VBZ been_VBN shown_VBN to_TO initiate_VB caspase_NN driven_VBN apoptosis_NNS in_IN
        a_DT manner_NN distinct_JJ from_IN chemotherapeutic_JJ agents_NNS such_JJ as_IN
        cisplatinum_NN ,_, etoposide_NN ,_, and_CC tamoxifen_NN ,_, which_WDT directly_RB cause_VB
        DNA_NNP damage_NN and_CC tend_VBP to_TO favor_VB ERCC_NNP 1_CD activation_NN [_NN 37_CD 38_CD ]_NN
        ._.
        Previous_JJ studies_NNS have_VBP shown_VBN that_DT truncation_NN of_IN the_DT
        highly_RB acidic_JJ carboxy-region_JJ BRCT_NNP resulted_VBD in_IN resistance_NN to_TO
        caspase_NN induced_VBD apoptosis_NNS [_NN 17_CD ]_NN ._. Further_RB ,_, this_DT failure_NN of_IN
        apoptosis_NNS was_VBD traced_VBN specifically_RB to_TO caspase_NN 8_CD and_CC the_DT
        Fas_NNP /_NN FasL_NNP pathway_NN ._. In_IN contrast_NN ,_, our_PRP$ data_NNS showed_VBD that_IN the_DT
        185_CD delAG_NN mutation_NN ,_, affecting_VBG the_DT amino-terminal_JJ domain_NN of_IN
        BRCA_NNP 1_CD ,_, conferred_VBD an_DT increased_VBN apoptotic_JJ response_NN with_IN no_DT
        caspase_NN pathway_NN preferentially_RB selected_VBD ._. Instead_RB ,_, this_DT
        amino-terminal_JJ mutation_NN favored_VBN elevated_VBD caspase_NN 3_CD levels_NNS
        that_WDT subsequently_RB facilitated_JJ enhanced_VBN apoptosis_NNS by_IN
        inactivating_VBG the_DT caspase-dependent_JJ DNA_NNP repair_NN proteins_NNS PARP_NNP
        and_CC by_IN inactivating_VBG DFF_NNP 45_CD ,_, an_DT inhibitor_NN of_IN the_DT
        caspase-dependent_JJ DNase_NNP ,_, DFF_NNP 40_CD ._. The_DT nature_NN of_IN the_DT 185_CD delAG_NN
        frameshift_NN makes_VBZ it_PRP difficult_JJ to_TO determine_VB if_IN the_DT apoptotic_JJ
        alterations_NNS seen_VBN are_VBP directly_RB caused_VBN by_IN the_DT mutation_NN or_CC by_IN
        downstream_JJ effects_NNS of_IN it_PRP and_CC certainly_RB deserves_VBZ further_JJ
        scrutiny_NN ._. In_IN this_DT way_NN ,_, carboxy-_NN and_CC amino-terminal_JJ BRCA_NNP 1_CD
        mutations_NNS may_MD target_VB two_CD distinct_JJ anti-apoptotic_JJ pathways_NNS ._.
        Therefore_RB ,_, disruptions_NNS in_IN either_DT or_CC both_DT BRCA_NNP 1_CD terminals_NNS
        effect_NN apoptotic_JJ response_NN ._.
        In_IN summary_NN ,_, our_PRP$ findings_NNS suggest_VBP a_DT possible_JJ novel_NN
        mechanism_NN by_IN which_WDT the_DT amino-terminal_JJ of_IN BRCA_NNP 1_CD suppresses_NNS
        apoptosis_NNS and_CC facilitates_NNS DNA_NNP repair_NN in_IN human_JJ ovarian_NN
        surface_NN epithelial_NN cells_NNS ._.
      
      
        Conclusions_NNP
        The_DT 185_CD delAG_NN mutation_NN in_IN the_DT BRCA_NNP 1_CD gene_NN disrupts_NNS the_DT
        zinc_NN linker_NN region_NN of_IN the_DT amino-terminal_JJ RING_NNP domain_NN ._.
        Disruption_NNP of_IN this_DT domain_NN triggered_VBD an_DT elevated_VBD caspase_NN
        3_CD -_: dependent_JJ apoptotic_JJ response_NN and_CC affected_VBN downstream_JJ
        proteins_NNS such_JJ as_IN DFF_NNP 45_CD and_CC PARP_NNP ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Cell_NNP Culture_NNP
          SV-_NNP 40_CD large_JJ T-_NNP antigen_NN transfected_JJ human_JJ ovarian_NN
          surface_NN epithelial_NN cell_NN lines_NNS ,_, MCC_NNP 5_CD and_CC HIO_NNP 3261_CD -_: 77_CD ,_, were_VBD
          derived_VBN from_IN women_NNS with_IN and_CC without_IN a_DT family_NN history_NN of_IN
          breast_NN /_NN ovarian_NN cancer_NN ,_, respectively_RB [_NN 31_CD ]_NN ._. While_IN MCC_NNP 5_CD
          cells_NNS were_VBD derived_VBN from_IN a_DT patient_NN denoted_JJ as_IN wild_JJ type_NN
          BRCA_NNP 1_CD status_NN ,_, HIO_NNP 3261_CD -_: 77_CD cells_NNS were_VBD derived_VBN from_IN a_DT
          patient_NN characterized_VBN as_IN 185_CD delAG_NN mutated_VBN [_NN 39_CD ]_NN ._. Dr_NNP ._. W_NNP ._.
          Bai_NNP (_( USF_NNP )_) kindly_RB provided_VBD the_DT MCF_NNP 7_CD breast_NN cancer_NN
          carcinoma_NN line_NN ._. Cells_NNP were_VBD maintained_VBN in_IN Medium_NNP 199_CD /_NN MCDB_NNP
          105_CD (_( 1_CD :_: 1_LS )_) (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) with_IN 5_CD %_NN fetal_JJ bovine_JJ
          serum_NN (_( GibcoBRL_NNP ,_, Rockville_NNP ,_, MD_NNP )_) and_CC 10_CD ug_NN /_NN ml_NN gentamicin_NN
          (_( GibcoBRL_NNP )_) in_IN 5_CD %_NN CO_NNP 
          2_CD /_NN 95_CD %_NN air_NN at_IN 37_CD °_NN C_NNP as_IN described_VBN
          previously_RB [_NN 31_CD 40_CD ]_NN ._.
        
        
          Induction_NNP of_IN Apoptosis_NNP and_CC Cell_NNP Viability_NNP
          Assessment_NNP
          Cells_NNP were_VBD grown_VBN in_IN 100_CD mm_NN tissue_NN culture_NN disks_NNS until_IN
          confluent_NN ._. Cultures_NNP were_VBD treated_VBN with_IN 1_CD μM_NN staurosporine_NN
          (_( STS_NNP )_) (_( Sigma_NNP )_) in_IN serum_NN containing_VBG medium_NN until_IN collected_VBN ._.
          Control_NN samples_NNS were_VBD rinsed_JJ in_IN DPBS_NNP ,_, drained_VBN ,_, and_CC fresh_JJ
          medium_NN was_VBD added_VBN ._.
          Cell_NNP growth_NN was_VBD determined_VBN by_IN the_DT MTS_NNP (_( Promega_NNP ,_,
          Madison_NNP ,_, WI_NNP )_) colorimetric_JJ assay_NN following_VBG STS_NNP treatment_NN ._.
          The_DT assay_NN was_VBD performed_VBN in_IN 96_CD well_RB microtiter_NN places_NNS
          according_VBG to_TO manufacturer_NN 's_POS instructions_NNS and_CC is_VBZ based_VBN on_IN
          soluble_JJ formazan_NN production_NN by_IN dehydrogenase_NN enzymes_NNS
          found_VBD in_IN metabolically_RB active_JJ cells_NNS ._. Samples_NNP were_VBD seeded_VBN
          in_IN six_CD wells_NNS per_IN time_NN point_NN at_IN 2_CD ._. 5_CD ×_NN 10_CD 3_CD cells_NNS per_IN well_RB ._.
          Absorbance_NNP was_VBD determined_VBN at_IN 490_CD nm_NN using_VBG a_DT Dynex_NNP MRX_NNP
          plate_NN reader_NN (_( Dynex_NNP Technologies_NNPS ,_, Chantilly_NNP ,_, VA_NNP )_) and_CC the_DT
          results_NNS expressed_VBD as_IN the_DT mean_JJ absorbance_NN of_IN triplicate_NN
          experiments_NNS ±_NN SE_NNP ._.
        
        
          SDS-PAGE_NNP and_CC Western_NNP Blot_NNP Analysis_NNP
          In_IN order_NN to_TO observe_VB changes_NNS at_IN the_DT onset_NN of_IN apoptosis_NNS ,_,
          only_RB adherent_NN cell_NN populations_NNS were_VBD trypsinized_JJ ,_, pelleted_JJ
          5_CD minutes_NNS at_IN 500_CD ×_NN g_SYM ,_, and_CC lysed_JJ in_IN ice_NN cold_JJ lysis_NNS buffer_NN
          (_( 10_CD mM_NN Tris-_NNP HCl_NNP (_( pH_NN 7_CD ._. 5_LS )_) ,_, 1_CD mM_NN MgCl_NNP 
          2_CD ,_, 1_CD mM_NN EGTA_NNP ,_, 0_CD ._. 1_CD mM_NN PMSF_NNP ,_, 5_CD mM_NN
          β-mercaptoethanol_JJ ,_, 0_CD ._. 5_CD %_NN CHAPS_NNP ,_, 10_CD %_NN glycerol_NN )_) for_IN 30_CD
          minutes_NNS at_IN 4_CD °_NN C_NNP ._. Lysates_NNP were_VBD then_RB centrifuged_JJ at_IN 100_CD ,_, 000_CD
          ×_NN g_SYM for_IN 1_CD h_NN at_IN 4_CD °_NN C_NNP ._. Protein_NNP concentrations_NNS of_IN the_DT lysates_NNS
          were_VBD determined_VBN using_VBG the_DT DC_NNP Protein_NNP Assay_NNP (_( Biorad_NNP ,_,
          Hercules_NNP ,_, CA_NNP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS
          instructions_NNS ._. Fifteen_CD micrograms_NNS of_IN protein_NN were_VBD added_VBN to_TO
          4_CD X_NNP loading_NN buffer_NN (_( 250_CD mM_NN Tris_NNP pH_NN 6_CD ._. 8_CD ,_, 8_CD %_NN SDS_NNP ,_, 20_CD %_NN
          glycerol_NN ,_, 0_CD ._. 012_CD %_NN bromophenol_NN blue_JJ ,_, 4_CD %_NN β-mercaptoethanol_JJ )_) ,_,
          heated_VBN to_TO 95_CD °_NN C_NNP for_IN 5_CD minutes_NNS ,_, electrophoresed_JJ in_IN 12_CD ._. 5_LS %_NN
          SDS-polyacrylamide_NNP gels_NNS ,_, and_CC transferred_VBD to_TO
          nitrocellulose_NN membrane_NN (_( Amersham_NNP Piscataway_NNP ,_, NJ_NNP )_) via_IN
          semi-dry_JJ transfer_NN ._. Due_JJ to_TO the_DT high_JJ molecular_JJ weight_NN of_IN
          PARP_NNP ,_, SDS-PAGE_NNP was_VBD performed_VBN using_VBG 7_CD %_NN polyacrylamide_NN
          gels_NNS ,_, and_CC proteins_NNS were_VBD then_RB transferred_VBN to_TO PVDF_NNP membrane_NN
          (_( Biorad_NNP )_) via_IN wet_JJ transfer_NN ._. All_DT membranes_NNS were_VBD blocked_VBN for_IN
          1_CD hour_NN with_IN 5_CD %_NN non-fat_JJ milk_NN Tris_NNP Buffered_NNP Saline_NNP plus_CC
          0_CD ._. 1_CD %_NN Tween-_NNP 20_CD (_( T-TBS_NNP )_) and_CC incubated_JJ at_IN least_JJS overnight_JJ at_IN
          4_CD °_NN C_NNP in_IN primary_JJ antibody_NN ._.
          Polyclonal_NNP antibodies_NNS to_TO caspase_NN 3_CD ,_, caspase_NN 9_CD ,_, and_CC
          PARP_NNP were_VBD purchased_VBN from_IN Cell_NNP Signaling_NNP (_( Beverly_NNP ,_, MA_NNP )_) ,_, a_DT
          monoclonal_NN antibody_NN to_TO caspase_NN 7_CD and_CC a_DT polyclonal_NN
          antibody_NN to_TO DFF_NNP 45_CD were_VBD obtained_VBN from_IN BD_NNP Transduction_NNP (_( San_NNP
          Diego_NNP ,_, CA_NNP )_) ._. Polyclonal_NNP anti-caspase_JJ 9_CD ,_, and_CC monoclonal_NN
          actin_NN antibodies_NNS were_VBD purchased_VBN from_IN Alexis_NNP (_( San_NNP Diego_NNP ,_,
          CA_NNP )_) and_CC Sigma_NNP ,_, respectively_RB ._. Membranes_NNP were_VBD incubated_JJ and_CC
          developed_VBN according_VBG to_TO the_DT Enhanced_NNP Chemiluminescent_NNP
          Protocol_NNP ,_, according_VBG to_TO manufacturer_NN 's_POS instructions_NNS
          (_( Amersham_NNP )_) ._. After_IN initial_JJ blotting_VBG ,_, membranes_NNS were_VBD
          reprobed_JJ for_IN actin_NN to_TO ensure_VB even_RB loading_NN ._.
          BRCA_NNP 1_CD status_NN of_IN the_DT cell_NN lines_NNS used_VBN in_IN this_DT study_NN was_VBD
          confirmed_VBN via_IN western_JJ immunoblotting_VBG ._. Cells_NNP were_VBD mixed_VBN
          with_IN equal_JJ volume_NN of_IN 2_CD X_NNP loading_NN buffer_NN ,_, vortexed_JJ and_CC
          boiled_VBD for_IN 5_CD minutes_NNS ._. One_CD hundred_CD thousand_CD cells_NNS were_VBD
          separated_VBN by_IN 5_CD %_NN SDS-PAGE_NNP ,_, transferred_VBN by_IN wet-transfer_JJ to_TO
          PVDF_NNP membrane_NN ,_, and_CC blotted_JJ as_IN described_VBN above_IN using_VBG
          monoclonal_NN antibody_NN specific_JJ for_IN the_DT N-_NNP terminus_JJ of_IN BRCA_NNP 1_CD
          (_( Oncogene_NNP Boston_NNP ,_, MA_NNP )_) ._. After_IN blotting_VBG ,_, the_DT PVDF_NNP membrane_NN
          was_VBD stained_JJ with_IN 2_CD %_NN amido_NN black_JJ in_IN 7_CD %_NN glacial_JJ acetic_JJ acid_NN
          and_CC the_DT protein_NN fronts_NNS of_IN all_DT lanes_NNS were_VBD compared_VBN for_IN
          loading_NN accuracy_NN ._.
        
        
          Statistical_NNP Analysis_NNP
          Samples_NNP for_IN MTS_NNP and_CC trypan_NN blue_JJ exclusion_NN assays_NNS were_VBD
          performed_VBN in_IN triplicate_NN and_CC the_DT data_NNS subjected_VBN to_TO the_DT
          Student_NNP 's_POS paired_VBN 
          t_NN -_: test_NN analysis_NN for_IN determination_NN
          of_IN statistical_JJ significance_NN between_IN BRCA_NNP 1_CD +_NN and_CC BRCA_NNP 1_CD wt_NN
          samples_NNS ._. Two-tailed_NNP results_NNS are_VBP reported_VBN as_IN P_NN values_NNS
          within_IN the_DT corresponding_JJ figures_NNS ._.
        
      
    
  
